This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Explore Content

The content of this website has been produced in line with the IBRANCE® Summary of Product Characteristics for Great Britain. IBRANCE® (palbociclib) Prescribing Information for Great Britain click here. IBRANCE® (palbociclib) Prescribing Information for Northern Ireland click here. Adverse event reporting information can be found at the bottom of the page.

Mode of Action

Confidence in a Treatment that's Setting the Standard1-2

​​​​​​​The growth of HR+ breast cancer is dependent on cyclin D1, a direct transcriptional target of the ER3-4
a. Cyclin D1 activates CDK4/6 resulting in G1–S phase transition and entry into the cell cycle3-4
b. Cell-line models of endocrine resistance remain dependent on cyclin D1 and  CDK4/63-4

IBRANCE® is an orally active selective inhibitor of CDK4 and CDK6 kinases.5-6

IBRANCE® blocks Rb phosphorylation at concentrations of 9–15 nmol/l, inducing G1 arrest in Rb+ tumour cell lines.5

Synergy between ER and CDK4/6 has led to IBRANCE® being developed in combination with endocrine therapy as treatment for HR+/HER2- mBC.6​​​​​​​​

Adapted from Cadoo KA, et al. Breast Cancer Targets and Therapy. 2004;6:123–33.2

ER : Oestrogen Receptor, HR+ : Hormone Receptor Positive, HER2- : Human Epidermal growth factor Receptor 2-negative, mBC : metastatic Breast Cancer

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for how to report adverse reactions.

References
  1. Rugo HS, et al. Breast Cancer Res Treat. 2019;174:719–29.
  2. Finn RS, et al. N Engl J Med. 2016;375:1925-1936.
  3. Thangavel C, et al. Endocr Relat Cancer. 2011;18:333–45.
  4. Cadoo KA, et al Breast Cancer Targets and Therapy. 2014;6:123–33.
  5. Fry DW, et al. Mol Cancer Ther. 2004;3:1427–38.
  6. VanArsdale T, et al. Clin Cancer Res. 2015;21:2905–10.
PP-IBR-GBR-3749. July 2021

PALOMA-2 Trial

IBRANCE® + Aromatase Inhibitor (AI) Clinical Trial Results

  • IBRANCE® PALOMA-2 Trial
  • Study Design
  • Efficacy Outcomes
  • Quality of Life Outcomes
  • Safety Profile
  • IBRANCE® Mode of Action

Clinical Trials

  • Clinical Trial results for IBRANCE®
  • IBRANCE® Clinical Trials
  • PALOMA-2 Trial

Safety

IBRANCE® safety information and outcomes

  • IBRANCE® Safety Profile
  • Neutropenia
  • Adverse Event Management

Indication

  • IBRANCE® is indicated for the treatment of HR+/HER2- locally advanced or metastatic breast cancer:
       - In combination with an aromatase inhibitor; or
    ​​​​​​​   - In combination with fulvestrant in women who have received prior ET

    In pre- or perimenopausal women, the ET should be combined with a LHRH agonist

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

Yes

No